Drug Trial Radar · NCT07185139
MSCohi-O Lenses for Ocular Involvement in Sjögren's Syndrome
Last checked: Nov 20, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Sep 12, 2025
Primary completion
Aug 30, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- Guangdong ProCapZoom Biosciences Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 22, 2025
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is aSingle-center, multiple-dosing, prospective, nonrandom, single-arm trial.
Conditions
- Sjögren's Syndrome
Interventions
MSCohi-O LensesDrug
Each subject will wear MSCohi-O Lenses for 12 hours a day, totally 14 wearings.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: from subjects receiving administration to Day 29 post-administration
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.